Owens & Minor (NYSE:OMI - Get Free Report) released its quarterly earnings results on Friday. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.53 by $0.02, Zacks reports. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. The firm had revenue of $2.70 billion during the quarter, compared to the consensus estimate of $2.68 billion. During the same quarter in the prior year, the firm earned $0.69 EPS. Owens & Minor's revenue for the quarter was up 1.5% on a year-over-year basis. Owens & Minor updated its FY25 guidance to $1.60-1.85 EPS and its FY 2025 guidance to 1.600-1.850 EPS.
Owens & Minor Trading Up 4.7 %
Shares of OMI stock traded up $0.44 during trading hours on Tuesday, hitting $9.76. 4,173,384 shares of the company were exchanged, compared to its average volume of 1,716,829. The firm has a market cap of $752.66 million, a PE ratio of -15.02, a PEG ratio of 0.20 and a beta of 0.48. Owens & Minor has a 1 year low of $6.07 and a 1 year high of $28.35. The company has a quick ratio of 0.45, a current ratio of 1.09 and a debt-to-equity ratio of 2.11. The firm has a fifty day moving average of $11.38 and a 200 day moving average of $13.14.
Owens & Minor declared that its Board of Directors has authorized a stock buyback program on Friday, February 28th that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 13.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its stock is undervalued.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Citigroup lowered their price target on shares of Owens & Minor from $21.00 to $18.50 and set a "buy" rating on the stock in a research note on Tuesday, November 5th. Barclays lowered their price objective on shares of Owens & Minor from $18.00 to $14.00 and set an "equal weight" rating on the stock in a research note on Tuesday, November 5th. Robert W. Baird increased their price objective on shares of Owens & Minor from $10.00 to $11.00 and gave the company a "neutral" rating in a research note on Monday. Finally, UBS Group lowered their price objective on shares of Owens & Minor from $25.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $15.08.
Get Our Latest Report on Owens & Minor
About Owens & Minor
(
Get Free Report)
Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.
Recommended Stories
Before you consider Owens & Minor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Owens & Minor wasn't on the list.
While Owens & Minor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
